Zembowicz A, Hatchett RJ, Radziszewski W, Gryglewski RJ
Figure 2 Cardiotoxic properties are mainly associated with high doses of CTX 120200 mg/kg usually administered over 25 days (90, 98, 99)
According to the researchers, their findings broadly suggest that small-molecule GLP-1s could have applications in dysregulating reward signaling, creating implications for the drugs treatment of substance-use disorder and binge-eating
Like its injectable counterpart, it also carries approval to reduce the risk of major adverse cardiovascular events (MACE), including cardiovascular death, heart attack, and stroke, in adults with established heart disease and obesity or overweight